Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 7/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5598534 | 1.00 | TSHR (0.57) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL19566738 | 1.00 | TSHR (0.57) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL19628851 | 0.95 | TSHR (0.52) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL9764407 | 0.94 | TSHR (0.59) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL9763692 | 0.94 | TSHR (0.54) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL9763752 | 0.94 | TSHR (0.59) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL9221742 | 0.92 | TSHR (0.52) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL9195450 | 0.92 | TSHR (0.52) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL10005277 | 0.90 | TSHR (0.59) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL14559754 | 0.88 | TSHR (0.45) | TSHRALDH1A1CYP3A4HPGDTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069529-A1 | TOPICAL COMPOSITIONS OF MICROCOCCUS LUTEUS Q24 AND USE THEREOF | BLIS TECH LIMITED (NZ) | 2026-03-12 | — | — | US | claimed |
| US-12559595-B2 | Curable resin compositions | ILLUMINA, INC. (US) | 2026-02-24 | — | — | US | claimed |
| US-20260035745-A1 | RESIN COMPOSITION AND FLOW CELLS INCORPORATING THE SAME | ILLUMINA INC (US) | 2026-02-05 | — | — | US | claimed |
| US-12442039-B2 | Resin composition and flow cells incorporating the same | ILLUMINA, INC. (US) | 2025-10-14 | — | — | US | claimed |
| EP-4580597-A1 | TOPICAL COMPOSITIONS OF MICROCOCCUS LUTEUS Q24 AND USE THEREOF | Blis Technologies Limited (NZ) | 2025-07-09 | — | — | EP | claimed |
| CN-112673029-B | Resin composition and flow cell incorporating the same | 伊鲁米那股份有限公司 | 2025-01-07 | — | — | CN | claimed |
| EP-4405749-A2 | CURABLE RESIN COMPOSITIONS | Illumina, Inc. (US) | 2024-07-31 | — | — | EP | claimed |
| US-11975478-B2 | Flow cells | ILLUMINA CAMBRIDGE LIMITED (GB) | 2024-05-07 | — | — | US | claimed |
| CN-117813549-A | Curable resin composition | 因美纳有限公司 | 2024-04-02 | — | — | CN | claimed |
| WO-2024047589-A1 | TOPICAL COMPOSITIONS OF MICROCOCCUS LUTEUS Q24 AND USE THEREOF | BLIS TECHNOLOGIES LIMITED (NZ) | 2024-03-07 | — | — | WO | claimed |
| EP-4301332-A1 | TOPICAL COMPOSITION AND USE THEREOF | Blis Technologies Limited (NZ) | 2024-01-10 | — | — | EP | claimed |
| WO-2023046813-A2 | CURABLE RESIN COMPOSITIONS | ILLUMINA CAMBRIDGE LIMITED (GB) | 2023-03-30 | — | — | WO | claimed |
| EP-4139744-A1 | FLOW CELLS | Illumina Cambridge Limited (GB) | 2023-03-01 | — | — | EP | claimed |
| WO-2022185238-A1 | TOPICAL COMPOSITION AND USE THEREOF | BLIS TECHNOLOGIES LIMITED (NZ) | 2022-09-09 | — | — | WO | claimed |
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | claimed |
| CN-114207518-A | Flow cell | 伊鲁米纳剑桥有限公司 | 2022-03-18 | — | — | CN | claimed |
| US-20210339457-A1 | FLOW CELLS | ILLUMINA CAMBRIDGE LIMITED (GB) | 2021-11-04 | — | — | US | claimed |
| WO-2021214037-A1 | FLOW CELLS | ILLUMINA CAMBRIDGE LIMITED (GB) | 2021-10-28 | — | — | WO | claimed |
| US-12611666-B2 | Substrate with orthogonally functional nanodomains | ILLUMINA, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-0433906-A2 | Thermoplastic resin and process for producing the same | TOSHIBA SILICONE CO., LTD. (JP) | 1991-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069529-A1 | TOPICAL COMPOSITIONS OF MICROCOCCUS LUTEUS Q24 AND USE THEREOF | LIPA, LPL, LCT | TSHR 4447/4885ALDH1A1 3202/4885CYP3A4 2012/4885 |
| US-20260035745-A1 | RESIN COMPOSITION AND FLOW CELLS INCORPORATING THE SAME | FLNA, ACTN4, ACTN1 | TSHR 3767/4885ALDH1A1 846/4885CYP3A4 2527/4885 |
| US-12559595-B2 | Curable resin compositions | ACR, RARA, RAD51 | TSHR 2955/4885ALDH1A1 270/4885CYP3A4 2107/4885 |
| US-12611666-B2 | Substrate with orthogonally functional nanodomains | DNMT3A, DNMT1, POLM | TSHR 3409/4885ALDH1A1 986/4885CYP3A4 4172/4885 |
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | TSHR 1902/4885ALDH1A1 4556/4885CYP3A4 4682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.